Piramal Pharma Q2 FY27 Results: EBITDA Jumps 132% to ₹366 Crore, Profit Turns Positive

Piramal Pharma returned to consolidated profitability in Q2 FY27, reporting a net profit of ₹5.6 crore against a loss of ₹99.22 crore last year.

Revenue grew 28% to ₹2,617.06 crore, while EBITDA increased 132% to ₹366 crore. The company also raised its FY27 revenue growth outlook to 19–20%.

Piramal Pharma Q2 FY27 Financial Performance

Metric	Q2 FY27	Q2 FY26
Revenue from operations	₹2,617.06 crore	₹2,043.72 crore
EBITDA	₹366 crore	₹158 crore
EBITDA margin	14%	7.73%
Profit before tax	₹81.63 crore	Loss of ₹46.18 crore
Net profit/(loss)	₹5.6 crore	Loss of ₹99.22 crore
Basic EPS	₹0.04	-₹0.75

EBITDA margin improved to 14% from 7.73%, an expansion of 627 basis points.

Segment-Wise Revenue Growth

All three business segments recorded year-on-year revenue growth.

Business segment	Revenue	YoY growth
CDMO	₹1,424 crore	36%
Complex Hospital Generics (CHG)	₹849 crore	32%
Piramal Consumer Healthcare (PCH)	₹359 crore	13%

The CDMO business added 22 new customers during H1 FY27. Its antibody-drug conjugate revenue grew 51%.

PCH Power Brands recorded 21% growth, while e-commerce sales increased 32%. The CHG business maintained a 48% value share in the US Sevoflurane market.

Yapan Bio Stake Rises to 74%

Piramal Pharma acquired an additional 40.67% stake in Yapan Bio Private Limited for ₹76.09 crore.

The acquisition increased its total shareholding to 74%, making Yapan Bio a subsidiary effective August 18, 2026. Yapan Bio specialises in vaccines and biologics.

FY27 Revenue Growth Outlook Upgraded

Piramal Pharma raised its FY27 revenue growth guidance to 19–20%, supported by strong first-half performance.

Its distribution agreement with Bayer is scheduled to expire in December 2026. The company expects the transition to have no material impact on its FY27 guidance.

Standalone Profit Declines

Despite revenue growth, standalone net profit fell 13% year-on-year to ₹170.74 crore. Standalone revenue increased 19% to ₹1,345.38 crore.

Higher employee and other expenses, along with lower other income, contributed to the decline in standalone profit.

Piramal Pharma Share Price Returns

Period	Return
1 day	+1.82%
5 days	+2.20%
1 month	-5.51%
6 months	+20.09%
1 year	-1.80%
5 years	+7.10%

Piramal Pharma’s Q2 FY27 results showed a return to consolidated profitability, higher EBITDA and growth across all three business segments. Its ability to sustain margins and meet the upgraded FY27 outlook will remain important to monitor.

This article is for informational purposes only and is not investment advice.

What were Piramal Pharma's Q2 FY27 results?

Piramal Pharma reported consolidated net profit of ₹5.6 crore in Q2 FY27, compared with a net loss of ₹99.22 crore in Q2 FY26. Revenue from operations increased 28% year-on-year to ₹2,617.06 crore.

How much did Piramal Pharma's EBITDA grow in Q2 FY27?

Piramal Pharma's EBITDA rose 132% year-on-year to ₹366 crore from ₹158 crore in the corresponding quarter last year.

What was Piramal Pharma's EBITDA margin in Q2 FY27?

The company's consolidated EBITDA margin increased to 14% from 7.73% in Q2 FY26, an improvement of 627 basis points.

What is Piramal Pharma's revenue growth guidance for FY27?

Piramal Pharma upgraded its FY27 revenue growth outlook to 19–20%, citing strong first-half performance and continued business momentum.

Which Piramal Pharma business segment recorded the highest revenue growth?

The Contract Development and Manufacturing Organization (CDMO) segment recorded the highest growth among the three reported segments, with revenue increasing 36% year-on-year to ₹1,424 crore.

What is the Yapan Bio acquisition by Piramal Pharma?

Piramal Pharma acquired an additional 40.67% stake in Yapan Bio Private Limited for ₹76.09 crore, increasing its total shareholding to 74%. Yapan Bio specialises in vaccines and biologics.

How did Piramal Pharma's standalone profit perform in Q2 FY27?

Standalone net profit declined 13% year-on-year to ₹170.74 crore from ₹196.33 crore, even as standalone revenue increased 19% to ₹1,345.38 crore.

Why did Piramal Pharma return to consolidated profitability?

Piramal Pharma's consolidated performance improved alongside 28% revenue growth, a 132% increase in EBITDA and stronger results across its CDMO, Complex Hospital Generics and Consumer Healthcare businesses.

Is Piramal Pharma's Q2 FY27 performance positive for investors?

The return to consolidated profitability, higher EBITDA and upgraded revenue guidance indicate improved operating performance. Investors may also monitor margins, costs and the company's ability to meet its FY27 outlook. This information is not investment advice.